IO Biotech (IOBT) Competitors $0.92 -0.02 (-1.83%) As of 04/24/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IOBT vs. DRUG, MNPR, NVCT, LFCR, YMAB, SLRN, IMMP, PROK, HUMA, and ITOSShould you be buying IO Biotech stock or one of its competitors? The main competitors of IO Biotech include Bright Minds Biosciences (DRUG), Monopar Therapeutics (MNPR), Nuvectis Pharma (NVCT), Lifecore Biomedical (LFCR), Y-mAbs Therapeutics (YMAB), Acelyrin (SLRN), Immutep (IMMP), ProKidney (PROK), Humacyte (HUMA), and iTeos Therapeutics (ITOS). These companies are all part of the "pharmaceutical products" industry. IO Biotech vs. Bright Minds Biosciences Monopar Therapeutics Nuvectis Pharma Lifecore Biomedical Y-mAbs Therapeutics Acelyrin Immutep ProKidney Humacyte iTeos Therapeutics Bright Minds Biosciences (NASDAQ:DRUG) and IO Biotech (NASDAQ:IOBT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability, institutional ownership and community ranking. Does the MarketBeat Community favor DRUG or IOBT? IO Biotech received 19 more outperform votes than Bright Minds Biosciences when rated by MarketBeat users. However, 100.00% of users gave Bright Minds Biosciences an outperform vote while only 92.59% of users gave IO Biotech an outperform vote. CompanyUnderperformOutperformBright Minds BiosciencesOutperform Votes6100.00% Underperform VotesNo VotesIO BiotechOutperform Votes2592.59% Underperform Votes27.41% Do institutionals and insiders believe in DRUG or IOBT? 40.5% of Bright Minds Biosciences shares are owned by institutional investors. Comparatively, 54.8% of IO Biotech shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by insiders. Comparatively, 2.3% of IO Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts rate DRUG or IOBT? Bright Minds Biosciences presently has a consensus price target of $84.33, indicating a potential upside of 152.34%. IO Biotech has a consensus price target of $9.33, indicating a potential upside of 911.41%. Given IO Biotech's stronger consensus rating and higher probable upside, analysts plainly believe IO Biotech is more favorable than Bright Minds Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bright Minds Biosciences 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20IO Biotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Is DRUG or IOBT more profitable? Bright Minds Biosciences' return on equity of -5.85% beat IO Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Bright Minds BiosciencesN/A -5.85% -5.68% IO Biotech N/A -86.56%-75.24% Which has better earnings & valuation, DRUG or IOBT? Bright Minds Biosciences is trading at a lower price-to-earnings ratio than IO Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBright Minds BiosciencesN/AN/A-$2.06M-$0.17-196.59IO BiotechN/AN/A-$86.08M-$1.37-0.67 Which has more risk and volatility, DRUG or IOBT? Bright Minds Biosciences has a beta of -5.5, suggesting that its share price is 650% less volatile than the S&P 500. Comparatively, IO Biotech has a beta of 0.08, suggesting that its share price is 92% less volatile than the S&P 500. Does the media favor DRUG or IOBT? In the previous week, Bright Minds Biosciences had 2 more articles in the media than IO Biotech. MarketBeat recorded 2 mentions for Bright Minds Biosciences and 0 mentions for IO Biotech. IO Biotech's average media sentiment score of 1.87 beat Bright Minds Biosciences' score of 1.26 indicating that IO Biotech is being referred to more favorably in the news media. Company Overall Sentiment Bright Minds Biosciences Positive IO Biotech Very Positive SummaryBright Minds Biosciences beats IO Biotech on 8 of the 15 factors compared between the two stocks. Get IO Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for IOBT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IOBT vs. The Competition Export to ExcelMetricIO BiotechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$60.80M$6.59B$5.41B$7.70BDividend YieldN/A3.21%5.44%4.33%P/E Ratio-0.677.0522.1818.31Price / SalesN/A273.45397.31107.09Price / CashN/A65.6738.2034.62Price / Book0.466.506.834.25Net Income-$86.08M$142.50M$3.20B$247.51M7 Day Performance7.29%8.32%5.77%6.86%1 Month Performance-21.13%-5.61%-4.32%-2.95%1 Year Performance-36.36%0.11%17.88%5.17% IO Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IOBTIO Biotech3.0838 of 5 stars$0.92-1.8%$9.33+911.4%-36.8%$60.80MN/A-0.6730Positive NewsDRUGBright Minds Biosciences3.3453 of 5 stars$32.75+13.6%$84.33+157.5%+2,966.1%$230.69MN/A-192.64N/APositive NewsMNPRMonopar Therapeutics1.0703 of 5 stars$37.49+7.5%$55.33+47.6%+1,256.8%$229.18MN/A-19.0310Positive NewsGap UpNVCTNuvectis Pharma2.0274 of 5 stars$9.78+17.7%$15.67+60.2%+63.3%$228.77MN/A-8.438Positive NewsGap UpLFCRLifecore Biomedical1.8493 of 5 stars$6.17+6.0%$8.00+29.7%-2.5%$228.44M$130.86M-11.02690YMABY-mAbs Therapeutics3.6166 of 5 stars$4.93+2.1%$18.30+271.2%-73.0%$222.93M$87.69M-9.13150Analyst DowngradeNews CoveragePositive NewsSLRNAcelyrin3.4153 of 5 stars$2.18-2.2%$9.60+340.4%-52.5%$219.98MN/A-0.89135Positive NewsIMMPImmutep1.0512 of 5 stars$1.49+2.1%$8.50+470.5%-35.1%$216.88M$5.14M0.002,021Positive NewsPROKProKidney2.3738 of 5 stars$0.74+1.2%$5.00+575.7%-63.5%$216.60M$76,000.00-1.353Insider TradePositive NewsHUMAHumacyte2.275 of 5 stars$1.49-2.6%$13.71+820.4%-61.3%$215.82M$1.57M-1.11150Positive NewsGap DownITOSiTeos Therapeutics2.2831 of 5 stars$5.53-2.1%$25.75+365.6%-29.4%$211.21M$35M-1.7690Positive News Related Companies and Tools Related Companies Bright Minds Biosciences Competitors Monopar Therapeutics Competitors Nuvectis Pharma Competitors Lifecore Biomedical Competitors Y-mAbs Therapeutics Competitors Acelyrin Competitors Immutep Competitors ProKidney Competitors Humacyte Competitors iTeos Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IOBT) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IO Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IO Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IOBT Stock Free IOBT Stock Alerts